Published on: November 8, 2024

Published on 08 November 2024

As of 08 November 2024, the Health Technology Assessment (HTA) Council hereby makes public its preliminary recommendations on the possible inclusion in the Philippine National Formulary (PNF) and thus the government financing of the following health technologies, for stakeholder feedback/comments:

  • Abacavir/Lamivudine 120 mg/60 mg dispersible tablet (ABC/3TC) for treatment of human immunodeficiency virus (HIV) in pediatric population.
  • Levonorgestrel 52 mg intrauterine delivery (IUD) system for contraception.
  • Levonorgestrel 75mg subdermal implant for contraception.
  • Multiple Micronutrient Supplement Capsule (60s) for
    • Prevention of vitamin and mineral deficiencies
    • Improvement of iron status, and reduction of anemia among pregnant and lactating women
  • Sodium Chloride + Potassium Chloride + Calcium Lactate Pentahydrate 1.544 g/83.16 mg/63.13 mg per sachet powder for reconstitution as adjunctive treatment for sinusitis.

These health technologies were reviewed against clinical practice guidelines (CPGs) [local and approved by the Department of Health (DOH); and/or international, but locally adopted guidelines],  existing recommendations by the World Health Organization (WHO), and DOH Omnibus Health Guidelines (OHG). Further, costing analyses of these health technologies were performed. The supporting evidence reviewed and discussed by the HTA Council are shown below.

All comments, inputs, and/or appeals on the above preliminary recommendation may be submitted until 22 November 2024 (Friday), for the consideration of the HTA Council, through email at hta@dost.gov.ph. 

Please use the prescribed form for appeals indicated in the official HTA Philippines website [https://hta.dost.gov.ph/appeals-2/]. Appeals not following the prescribed format, and those submitted beyond the deadline shall not be entertained.

Should you have any questions or concerns regarding the preliminary recommendation, please do not hesitate to contact us through the same email address or via telephone call via (02) 8875-7734 local 260.  

Preliminary-HTA-Council-Recommendation-on-Abacavir_Lamivudine-Levonorgestrel-MMS-Sodium-Cl-08-November-2024Download